Topline results from OPUS-1, a pivotal Phase III study of SAR 1118 (lifitegrast ophthalmic solution), from SARcode, for the treatment...
The FDA has requested an additional clinical study as part of a complete response letter (CRL) to the new drug...
Shire plc has announced it has resubmitted the New Drug Application (NDA) to the FDA for its investigational candidate, lifitegrast...